Abstracts

Impact of Switching From Dual to Triple Therapy on Inflammation: INSTINCT Study

Background: Because inflammation is associated with mortality and has been linked to HIV transcription in lymphoid tissues during ART, it is necessary to address the long-term effects of switching ART regimens with different numbers of antiretrovirals on inflammation. Methods: In this interim analysis of the randomized, open-label, multicenter INSTINCT trial (clinicaltrial.gov: NCT04076423), we evaluated the…

High-Dose VH3810109 (N6LS) ± Recombinant Human Hyaluronidase PH20: Phase I SPAN Study Safety Results

Background: Broadly neutralizing antibodies are being developed for long-acting HIV-1 therapy. VH3810109 (N6LS), a CD4-binding site antibody with broad and potent neutralization activity in vitro, demonstrated robust antiviral effect in adults with HIV-1 in the phase IIa BANNER study. Here, we report safety and tolerability for the highest subcutaneous (SC) and intravenous (IV) single N6LS…

Structure-Guided Optimization of InSTIs to Increase Antiviral Potencies Against HIV-1 IN Mutants

Background: There are at least four distinct resistance pathways that emerge against second-generation INSTIs: G118R, G140A/S + Q148H/K/R, N155H, and R263K. Although it is critical to develop INSTIs that retain potency against all four resistance pathways, an important aspect of our research has been directed at overcoming resistance associated with G140S/Q148H mutants, a pathway common…

Next-Generation Maturation Inhibitor GSK3640254 Showed Broad Spectrum Potency Without MI Resistance

Background: Background: HIV-1 maturation inhibitors (MI) offer a novel mechanism of action but have suffered from gag polymorphisms and decreased antiviral potency. GSK3640254 (GSK’254) is a next-generation MI that demonstrated broad spectrum coverage of gag polymorphisms in vitro (Dicker et al. AAC 2022;66:e0187621). GSK’254 + 2 nucleoside-reverse transcriptase inhibitors (NRTIs) demonstrated comparable efficacy to DTG…

Gendered Inclusion in Studies Evaluating Injectable HIV Treatment and PrEP: A Scoping Review

Background: Globally, 54% of people living with HIV (PLWH) are female (UNAIDS). Therapies containing long-acting injectable (LA-I) agents are included in treatment guidelines and licensed for pre-exposure prophylaxis (PrEP). In female participants, LA-I cabotegravir (CAB) is superior to oral PrEP. However, cisgender and transgender women are historically underrepresented in wider HIV research. Methods: We report…

Intramuscular Injection vs Intravenous Infusion of Ibalizumab for HTE PWH: The Results of TMB-302

Background: Ibalizumab (IBA) is a monoclonal antibody approved for the treatment of multi-drug resistant HIV-1 infection in heavily treatment experienced (HTE) people with HIV (PWH) in combination with an optimized background regimen. The efficacy of ibalizumab (IBA) in combination with an optimized background regimen has been demonstrated in clinical trials previously. IBA is currently administered…

Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Elderly Using PBPK Modelling

Background: The quality of life of people with HIV (PWH) has significantly increased thanks to potent single pill antiretroviral regimens characterized by a good tolerability. Another milestone has been reached with long-acting (LA) formulations which enable infrequent dosing. Clinical trials of LA agents were mostly conducted in standard populations, leading to a lack of knowledge…